Royal Fund Management 13F: Adds $3.2M to GILD Stake
Key Points
- Royal Fund Management disclosed an 827.3% increase in its Gilead Sciences, Inc. GILD holdings, adding 21,288 shares to finish the quarter with 23,861 shares valued at approximately $3.56 million in a filing on October 22, 2026.
- Gilead Sciences, Inc. GILD recently traded around $153.57, sitting below its 52-week high of $160.51, with trailing twelve-month revenue reaching $30.46 billion and an upcoming earnings report scheduled for October 29, 2026.
- Other financial firms also adjusted their positions in the drug maker, while company insiders completed several stock transactions and Wall Street analysts maintained a consensus buy rating on the shares.
Get Gilead Sciences text alerts
We text you when insiders, Congress, analysts or big funds move on $GILD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Royal Fund Management grew its stake in Gilead Sciences, Inc. GILD by 827.3% during the third quarter, according to a Form 13F filed with the SEC on October 22, 2026. The firm added 21,288 shares to bring its total holding to 23,861 shares.
GILD
Gilead Sciences, Inc.
What Changed in Royal Fund Management's Gilead Sciences Position
Royal Fund Management lifted its investment significantly during the period. The addition of 21,288 shares brought the fund's total position to 23,861 shares. Based on market values around the filing date, the stake was worth about $3.56 million, up from a prior holding of 2,573 shares.
Other Institutional Activity in Gilead Sciences
Other institutional investors also adjusted their positions in the biopharmaceutical firm around the same filing date. RMR Wealth Builders grew its holdings by 3,730 shares, ending with 42,950 shares worth about $6.40 million.
Gilead Sciences, Inc. Stock Down 1.7%
Gilead Sciences, Inc. GILD closed at $157.19 on October 22, 2026, and recently traded around $153.57 as of October 23, 2026. That puts the stock down about 2.3% since the filing date, while it remains up about 34.7% above its 52-week low of $114.02.
Recent Earnings
Gilead Sciences, Inc. GILD reported trailing twelve-month revenue of $30.46 billion alongside an EPS of -$2.65. The company's next earnings report is scheduled for October 29, 2026.
Dividend
Gilead Sciences, Inc. GILD pays an annual dividend of $3.28 per share.
Insider Buying and Selling at Gilead Sciences, Inc.
Company insiders executed several transactions prior to the filing. Director Anthony Welters disposed of 18,000 shares on August 26, 2026, valued at $2.68 million. Chief Executive Officer Daniel Patrick O'Day sold 15,000 shares worth $2.23 million on September 1, 2026. Chief Financial Officer Andrew D Dickinson sold 3,000 shares at $145.29 per share for a total of $435,870 on September 15, 2026. Officer Johanna Mercier also sold 3,000 shares valued at $432,646 on September 15, 2026.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. On October 7, 2026, Truist Securities maintained its buy rating and raised its target from $150.00 to $158.00. JP Morgan maintained an overweight rating on October 7, 2026, lifting its target from $160.00 to $170.00. RBC Capital maintained a sector perform rating on October 8, 2026, raising its target from $123.00 to $126.00. Cantor Fitzgerald reiterated an overweight rating with a target of $155.00 on October 8, 2026. B of A Securities maintained a buy rating on October 20, 2026, increasing its target from $168.00 to $172.00. The stock carries a consensus buy rating from 26 analysts with a mean price target of $160.15.
About Gilead Sciences
Gilead Sciences, Inc. GILD is a Foster City, California-based biopharmaceutical company that discovers and markets treatments for severe medical conditions, including therapies for HIV infections and other viral diseases.
Bottom Line
Investors will watch the upcoming earnings release on October 29, 2026, for further updates on revenue and profit trends.
Related Filing Alerts
Source: Royal Fund Management's 13F filing on $GILD (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts